IRIS
RUSSO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.786
NA - Nord America 1.306
AS - Asia 780
SA - Sud America 300
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.190
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.276
RU - Federazione Russa 891
SG - Singapore 310
PL - Polonia 281
BR - Brasile 263
CN - Cina 214
IE - Irlanda 177
SE - Svezia 135
IT - Italia 116
HK - Hong Kong 85
FR - Francia 80
VN - Vietnam 50
IN - India 27
DE - Germania 24
FI - Finlandia 19
BE - Belgio 16
CA - Canada 16
ID - Indonesia 16
AR - Argentina 14
UA - Ucraina 12
BD - Bangladesh 11
GB - Regno Unito 11
TR - Turchia 8
MX - Messico 7
PH - Filippine 7
UZ - Uzbekistan 7
CO - Colombia 6
IQ - Iraq 6
JP - Giappone 6
ZA - Sudafrica 6
EC - Ecuador 5
PK - Pakistan 5
AT - Austria 4
ES - Italia 4
KR - Corea 4
MY - Malesia 4
NL - Olanda 4
VE - Venezuela 4
AL - Albania 3
NP - Nepal 3
OM - Oman 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
EG - Egitto 2
HN - Honduras 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
LT - Lituania 2
PE - Perù 2
PY - Paraguay 2
SA - Arabia Saudita 2
UY - Uruguay 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CL - Cile 1
CR - Costa Rica 1
DZ - Algeria 1
EU - Europa 1
GT - Guatemala 1
GY - Guiana 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
MD - Moldavia 1
MN - Mongolia 1
MZ - Mozambico 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 4.190
Salva come PNG Salva come JPEG
Città #
Warsaw 278
Moscow 245
Ashburn 238
Dublin 177
Chandler 168
Singapore 159
Dallas 90
Hong Kong 85
Beijing 73
Nyköping 68
New York 47
Messina 45
Ann Arbor 43
The Dalles 43
Princeton 35
Dearborn 34
Jacksonville 34
San Jose 29
Lauterbourg 27
Los Angeles 27
Medford 27
Des Moines 24
Dong Ket 18
Cambridge 17
Brussels 16
Council Bluffs 16
Fort Washington 14
São Paulo 14
Wilmington 14
Buffalo 13
Ho Chi Minh City 13
Jakarta 11
Jinan 11
Tianjin 11
Houston 10
Munich 10
Belo Horizonte 8
Chennai 8
Guangzhou 8
Redondo Beach 8
Shenyang 8
Toronto 8
Woodbridge 8
Boardman 7
Falls Church 7
Hanoi 7
San Mateo 7
Seattle 7
Stockholm 7
Tashkent 7
Brooklyn 6
Hillsboro 6
Pune 6
San Francisco 6
Hebei 5
Nanjing 5
Rio de Janeiro 5
Santa Clara 5
Tokyo 5
Anagni 4
Brasília 4
Cagliari 4
Chicago 4
Curitiba 4
Dhaka 4
Dongdaemun-gu 4
Fairfield 4
Juiz de Fora 4
London 4
Mexico City 4
Mumbai 4
Nanchang 4
Nuremberg 4
Orem 4
Redwood City 4
Shanghai 4
Shenzhen 4
Zhengzhou 4
Amsterdam 3
Aracaju 3
Atlanta 3
Barretos 3
Bogotá 3
Brockport 3
Caloocan 3
Campinas 3
Diadema 3
Frankfurt am Main 3
Hangzhou 3
Indaiatuba 3
Johannesburg 3
Joinville 3
Manaus 3
Milan 3
Mogi Mirim 3
Montreal 3
Radomsko 3
Turku 3
Abidjan 2
Americana 2
Totale 2.478
Salva come PNG Salva come JPEG
Nome #
Exosomal PD-L1 expression and dynamic changes of immune response associated cytokines as predictive biomarkers for immune checkpoint blockage with PD-1/PD-L1 inhibitors in advanced/metastatic non-small cell lung cancer 258
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 238
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 202
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 182
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 179
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 176
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 172
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 168
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 162
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 152
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 149
Liquid biopsy tracking of lung tumor evolutions over time 146
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 144
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 142
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 142
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 137
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer 135
How I treat ALK-positive non-small cell lung cancer 134
Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario 133
1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable? 133
NSCLC and HER2: between lights and shadows 131
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data 126
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 125
Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study 124
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 119
Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC 116
Acquired resistance in oncogene-addicted non-small-cell lung cancer 111
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 73
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance. 71
Totale 4.280
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.559
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.559
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202179 0 0 0 0 0 0 0 0 0 49 10 20
2021/2022231 1 24 7 7 9 9 14 9 1 41 36 73
2022/2023533 38 56 19 44 35 48 7 45 221 3 12 5
2023/2024149 8 25 8 9 12 60 2 10 1 1 0 13
2024/2025637 3 5 7 36 60 18 52 155 125 28 45 103
2025/20261.901 102 110 127 112 160 393 255 283 285 74 0 0
Totale 4.280